|
|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
Industry Events |
 |
Evolution Summit
20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL
The 22nd Evolution Summit is the premium forum bringing leading drug
development executives and solution providers together. As an
invitation-only event, taking place behind closed doors, the Summit
offers an intimate environment for a focused discussion of key new
drivers shaping drug development.
More info >> |
|
 |
News and Press Releases |
 |
Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics
and reagents, is pleased to announce that several of the Affimer
reagents recently generated for development of a point-of-care COVID-19
antigen saliva test have now also been shown to block the interaction
between the virus’ spike protein and ACE2, a receptor on human cells
that is key to the virus infection pathway1.
More info >> |
|
|
